公众号 / 文章重症综合管理与镇静镇痛

使用多状态模型改进器官支持治疗试验的报告

Improving the Reporting of Trials Evaluating Organ Support Therapies Using Multistate Modeling.
PubMed 文献 · Am J Respir Crit Care Med · 2025-01-01
一句话结论多状态模型可直观分析器官支持治疗试验中患者状态转换的时间,比无器官支持天数更全面反映治疗效应。

ICU中器官支持治疗试验常以无器官支持天数为终点,但其复合性可能掩盖临床差异,且撤机成功定义、无支持期处理及死亡纳入方式不一,妨碍跨试验比较。多状态模型通过定义临床状态及状态间转换,可描述和比较整个随访期内患者轨迹。作者用两项近期随机对照试验重新分析,说明该框架能更清晰展示干预对状态转换时间的影响,提供更具临床相关性的治疗效应解读。作者结论认为多状态模型可实质性改进器官支持治疗试验的解释和主要分析。

要点

  • 无器官支持天数作为复合终点可能掩盖无器官支持天数相似患者间的重要临床差异。
  • 多状态模型通过定义临床状态及状态间转换,可描述和比较整个随访期内患者轨迹。
  • 对两项器官支持治疗随机对照试验重新分析显示,多状态框架能更清晰展示干预对状态转换时间的影响。
  • 撤机成功定义、无支持期间处理及死亡纳入方式不一致,使跨试验比较复杂化。
  • 作者结论认为多状态模型可实质性改进器官支持治疗试验的解释和主要分析。

研究设计与关键结果

  • 本文为方法学文章,描述多状态模型核心原则(包括马尔可夫假设)、优势与局限。
  • 作者选取两项近期评估器官支持治疗的随机对照试验,识别其主要统计挑战,并用多状态模型重新分析。
  • 多状态框架能更清晰展示干预如何影响临床状态间转换的时间,提供更丰富且更具临床相关性的治疗效应理解。

证据类型、等级与局限

  • 证据类型:方法学文章(综述类),非原始研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为多状态模型可实质性改进器官支持治疗试验的解释和主要分析。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「适用人群与场景」「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Rationale: Managing critically ill patients in the ICU often involves organ support therapies (OSTs), such as mechanical ventilation, extracorporeal membrane oxygenation, renal replacement therapy, and various pharmacologic strategies. Clinical trials in this context pursue diverse goals, including improving survival, reducing OST use, facilitating weaning, or comparing timing of OST initiation, which leads to substantial heterogeneity in OST-related endpoints. One commonly used outcome, the number of OST-free days, has been criticized for its composite nature, which can obscure important clinical differences between patients with similar OST-free day values. Variability in how weaning success is defined, how intercurrent OST-free periods are handled, and how death is incorporated further complicates comparisons across trials. Objectives: To illustrate how multistate modeling can offer an intuitive framework for analyzing randomized clinical trials involving OSTs and how this approach allows researchers to better describe and compare patient conditions during the entire follow-up. Methods: We describe the core principles of multistate modeling, including its assumptions (e.g., the Markov assumption), advantages, and limitations. We then present two recent randomized controlled trials evaluating OSTs and identify the main statistical challenges encountered in their analysis. Measurements and Main Results: Using a multistate modeling approach, we reanalyzed both trials to characterize and compare patient trajectories over time. The multistate framework enabled clearer insight into how interventions impact the timing of transitions between clinical states, providing a richer and more clinically relevant understanding of treatment effects. Conclusions: Multistate modeling can substantially inform the interpretation and primary analysis of a clinical trial evaluating an OST.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Hajage D, Gaudry S, Combes A, et al. Improving the Reporting of Trials Evaluating Organ Support Therapies Using Multistate Modeling. Am J Respir Crit Care Med. 2025. PMID: 40315144. doi:10.1164/rccm.202408-1669OC

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。